mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS (1987). "An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes". J. Biol. Chem. 262 (18): 8532–6. doi:10.1016/S0021-9258(18)47446-7. PMID 3597387. Fischer WH, Spiess J (1987). "Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides". Proc. Natl. Acad. Sci. U.S.A. 84 (11): 3628–32. Bibcode:1987PNAS...84.3628F. doi:10.1073/pnas.84.11.3628. PMC 304928. PMID 3473473. Messer M; Ottesen M (1965). "Isolation and properties of glutamine cyclotransferase of dried papaya latex". C. R. Trav. Lab. Carlsberg. 35 (1): 1–24. PMID 5846578.
Retiform hemangioendothelioma (hobnail hemangioendothelioma) Schwannoma (acoustic neuroma, neurilemmoma, neurinoma, neurolemmoma, Schwann cell tumor) Solitary angiokeratoma Solitary cutaneous leiomyoma Solitary mastocytoma Solitary neurofibroma (plexiform neurofibroma, solitary nerve sheath tumor, sporadic neurofibroma) Spider angioma (nevus araneus, spider telangiectasia, spider nevus, vascular spider) Spindle cell hemangioendothelioma (spindle cell hemangioma) Spindle cell lipoma Sternal cleft Subungual exostosis Superficial acral fibromyxoma Systemic mastocytosis Targetoid hemosiderotic hemangioma (hobnail hemangioma) Telangiectasia Telangiectasia macularis eruptiva perstans Teratoma Tufted angioma (acquired tufted angioma, angioblastoma, angioblastoma of Nakagawa, hypertrophic hemangioma, progressive capillary hemangioma, tufted hemangioma) Umbilical granuloma Universal angiomatosis (generalized telangiectasia) Urticaria pigmentosa (childhood type of generalized eruption of cutaneous mastocytosis) Venous lake (phlebectasis) Wildervanck syndrome Xanthelasmoidal mastocytosis Zosteriform metastasis
Less frequently employed treatments encompass prostaglandin pellets inserted into the urethra, the injection of smooth-muscle relaxants and vasodilators directly into the penis, penile implants, the use of penis pumps, and vascular surgery.
== Charity and volunteer work == In 1994, Kermani founded a language and cultural center in his parents' hometown of Isfahan, which he ran until 1997, the year the center had to close due to deteriorating German-Iranian relations. Since fall of 2014, Kermani has been serving as a patron of the initiative Willkommen für Flüchtlinge [Welcome to Refugees] via the Ehrenamt and Flüchtlinge [Volunteering and Refugees] project run by the Kölner Freiwilligenagentur [Cologne Volunteer Agency] which coordinates its offerings with the Kölner Flüchtlingsrat [Cologne Refugee Council].
Sources: en.wikipedia.org
Salvia divinorum is native to the Sierra Mazateca in Oaxaca, Mexico, where it is still used by the Mazatec, primarily to facilitate shamanic visions in the context of curing or divination. S. divinorum is one of several plant species with hallucinogenic properties that are ritually used by Mazatec shamans. In their rituals, the shamans use only freshly harvested S. divinorum leaves. They see the plant as an incarnation of the Virgin Mary, and begin the ritual with an invocation to Mary, Saint Peter, the Holy Trinity, and other saints. Ritual use traditionally involves being in a quiet place after ingestion of the leaf—the Maztec shamans say that "La Maria (S. divinorum) speaks with a quiet voice." It is also used in smaller amounts, as a diuretic, and to treat ailments including diarrhea, anemia, headaches, rheumatism, and a semi-magical disease known as panzón de borrego, or a swollen belly (literally, "lamb belly"). The history of the plant is not well known, and there has been no definitive answer to the question of its origin. Speculation includes Salvia divinorum being a wild plant native to the area; a cultigen of the Mazatecs; or a cultigen introduced by another Indigenous group. Botanists have also not been able to determine whether it is a hybrid or a cultigen.
==== Electrospinning ==== Electrospinning is a highly versatile technique that can be used to produce continuous fibers ranging in diameter from a few microns to a few nanometers. In a typical electrospinning set-up, the desired scaffold material is dissolved within a solvent and placed within a syringe. This solution is fed through a needle and a high voltage is applied to the tip and to a conductive collection surface. The buildup of electrostatic forces within the solution causes it to eject a thin fibrous stream towards the oppositely charged or grounded collection surface. During this process the solvent evaporates, leaving solid fibers leaving a highly porous network. This technique is highly tunable, with variation to solvent, voltage, working distance (distance from the needle to collection surface), flow rate of solution, solute concentration, and collection surface. This allows for precise control of fiber morphology. On a commercial level however, due to scalability reasons, there are 40 or sometimes 96 needles involved operating at once. The bottle-necks in such set-ups are: 1) Maintaining the aforementioned variables uniformly for all of the needles and 2) formation of "beads" in single fibers that we as engineers, want to be of a uniform diameter. By modifying variables such as the distance to collector, magnitude of applied voltage, or solution flow rate – researchers can dramatically change the overall scaffold architecture.
== Applications == Pumps that use oil either as their working fluid (diffusion pumps), or as their lubricant (mechanical rotary pumps), are often the sources of contamination in vacuum systems. Placing a cold trap at the mouth of such a pump greatly lowers the risk that oil vapours will backstream into the cavity. Cold traps can also be used for experiments involving vacuum lines such as small-scale very low temperature distillations/condensations. This is accomplished through the use of a coolant such as liquid nitrogen or a freezing mixture of dry ice in acetone or a similar solvent with a low melting point. Liquid nitrogen is only used when dry ice or other cryogenic approaches will not condense the desired gasses since liquid nitrogen will also condense oxygen. Any oxygen gas content in the vacuum line or any leak in the vacuum line will result in liquid oxygen mixed with the target vapors, often with explosive results. When performed on a larger scale, this technique is called freeze-drying, and the cold trap is referred to as the condenser. Cold traps are also used in cryopump systems to generate hard vacua by condensing the major constituents of the atmosphere (nitrogen, oxygen, carbon dioxide and water) into their liquid or solid forms. An igloo or other snow bivouac may exploit the same principle – confinement of denser cool air within an impermeable lower volume – to reduce cold air reaching the occupants through use of a sump or cill around a raised sleeping platform within.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.